Börsipäev 10. oktoober
Kommentaari jätmiseks loo konto või logi sisse
-
Esmaspäeval sulgusid Tallinna (+0.25%) ja Riia (+0.11%) indeksid plusspoolel ja Vilnius (-0.12%) miinuspoolel. Käibeks kujunes põhinimekirjas 423 tehinguga 821 tuhat eurot, millest Tallinna börsi käive moodustas 215 tehinguga 522 tuhat eurot ning Vilniuse börsi käive 169 tehinguga 258 tuhat eurot.
Enimkaubeldud aktsia oli eile Nordecon (0.00%) käibega 185 tuhat eurot ja tehingute arv oli 22 (s.h üks plokktehing EUR 1.380 x 100000). Järgnes Šiaulių bankas (+0.35%) 55 tehingu ja käibega 125 tuhat eurot. Tallink Grupp (+0.97%) aktsiaga tehti 35 tehingut kogumahus 89 tuhat eurot.
Kõige enam tõusid Grindeks (+3.90%, käive EUR 25k), Arco Vara (+1.25%, käive EUR 3k), Silvano Fashion Group (+1.13%, käive EUR 87k). Suurimad langejad olid PRFoods (-5.45%, käive EUR 800), Skano Group (-2.96%, käive EUR 900), Merko Ehitus (-1.04%, käive EUR 16k). -
Kuna Kolumbuse päeva tõttu olid USAs võlakirjaturud suletud ja makrouudiseid polnud, kujunes käive väga madalaks ka aktsiaturul. S&P 500 indeks lõpetas -0,2% kaotusega, kesisemalt esinesid esmaspäeval väikefirmad (Russell 2000 indeks -0,4%).
Euroopas võitis Stoxx 600 pärast reedest langust maad tagasi, kosudes elektri- ja gaasitootjate eestvedamisel 0,2%. Suurimat plussi näitasid indeksis Provident Financial +6.8%, Temenos Group +3.9%, Ferrari +3.5%, Man Group +3.3%, E.ON 3.1%. Langust vedasid K+S -8.2%, bpost -3.4%, Anglo American -3.4%, BPER Banca -3.2%, Chr Hansen Holding -2.8%.
Saksamaa tööstustoodang kasvas augustis 2,6% võrreldes juuliga, mis oli suurim hüpe rohkem kui kuue aasta jooksul ning ületas analüütikute 0,9% ootust. Valitsuse sõnul olid kasvu taga sõidukite tootjad, kuid kuises võrdluses aitas kaasa ka see, et osades regioonides langesid puhkused tehastes juulikuusse. Sestap võib septembri näitaja kujuneda taas mõnevõrra nõrgemaks, aga üldiselt viitab ettevõtete kõrge kindlustunne ja tellimuste sissevool sektori momentumi jätkumisele.
Tööstustoodangu statistika on päevakorras ka täna, mil oma augusti numbrid avaldavad Prantsusmaa, Itaalia ja Suurbritannia. Ühendriikides peaks väikeettevõtete küsitlus näitama kindlustunde püsimist ca 13 aasta kõrgeima taseme lähedal.
09.00 Saksamaa kaubavahetuse statistika (august)
09.45 Prantsusmaa tööstustoodang (august)
11.00 Itaalia tööstustoodang (august)
11.30 Suurbritannia tööstustoodang (august)
13.00 USA väikefirmade kindlustunde indeks (september)
17.00 FEDi Kashkari esineb -
Prantsusmaa tööstustoodang alanes augustis MoM -0,3% vs oodatud +0,4%. Osaliselt pehmendas allajäämist juuli kasvu revideerimine 0,5% pealt 0,8%le. Mullusega võrreldes aeglustus kasv 3,9% pealt 1,1%le.
-
Itaalia tööstustoodang kasvas augustis MoM 1,2%, ületades konsensuse 0,1% kasvuootust. Mullusega võrreldes paranes tulemus 5,7% võrra (oodati 2,9%)
-
Suurbritannia tööstustoodangu kuiseks kasvuks registreeriti augustis ootuspärased 0,2%, mis tõi kasvu aasta baasil 1,6%le. Konkreetsemalt töötlevas tööstuses oli pilt veidi parem (MoM 0,4% vs prog 0,2% ning YoY 2,8% vs prog 1,9%).
-
Gapping up
In reaction to strong earnings/guidance:
UAL +4.3%, (provides Q3 investor update; raised its Q3 pre-tax margin guidance and updated other metrics)
WMT +2.3%, (reaffirms FY18 guidance; sees FY19 EPS +5% with sales up at or above 3%; adds to share buyback)
REVG +1.1%
M&A news:
USEG +25.8% (sale of certain non-operated Williston Basin assets; received $2.0 million in cash)
PFE +1% (reviewing strategic alternatives for its Consumer Healthcare business)
HON +0.7% (announces planned comprehensive portfolio review)
Other news:
KALV +75.4% (enters collaboration agreement with Merck (MRK); Merck to pay $37 mln upfront payment, additionally take 9.9% stake through private placement at $8.50/share)
ANAB +57.1% (announces positive proof-of-concept data for ANB020)
PSDV +12.3% (enters strategic collaboration agreement with Nicox to develop sustained release drug to lower intraocular pressure in patients with glaucoma)
REPH +10.6% (presents clinical efficacy data from its Phase III study evaluating intravenous (IV) meloxicam 30mg)
OVID +8.2% (receives orphan drug designation from the U.S. FDA for OV101)
ICHR +5.9% (entered into 'substantial' agreement to produce liquid delivery systems for one of its key customers)
NVDA +4.2% (announces new Drive PX Pegasus AI hardware that enables fully autonomous (level 5) driving - TechCrunch)
ATRS +4% (enters into a definitive asset purchase agreement to sell the worldwide rights, including certain fixed assets, for the ZOMAJET )
ALDX +2.6% (announces new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis), CLVS +1.8% ( submitted sNDA to the FDA for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy)
DXC +1.2% (to acquire Logicalis SMC)
REVG +1.1% (announces an underwritten public offering of 10,000,000 shares of common stock by certain selling stockholders)
AGN +1% (FDA has accepted the NDA for ulipristal acetate)
Analyst comments:
ABEO +4% (initiated with a Buy at Citigroup)
PANW +2.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
RBS +2.5% (upgraded to Neutral from Underperform at Credit Suisse; upgraded to Neutral from Sell at Citigroup)
RIG +1.6% (initiated with Buy ratings at Deutsche Bank)
TSM +1.5% (upgraded to Overweight from Neutral at JP Morgan)
DVN +1.4% (upgraded to Buy at Jefferies)
DO +1.3% (upgraded to Neutral from Sell at FBR & Co)
TSLA +1.2% (target raised to $379 from $317 at Morgan Stanley)
LYG +0.8% (upgraded to Outperform from Neutral at Credit Suisse)
CXO +0.8% (upgraded to Buy at Jefferies)
CAT +0.7% (target raised to $158 at Goldman - new street high)
CLB +0.7% (initiated with Buy ratings at Deutsche Bank)
HAL +0.5% (initiated with Buy ratings at Deutsche Bank)
Gapping down
In reaction to disappointing earnings/guidance:
N/A.
Other news:
SRAX -4% (after closing near highs -- up 43% on the day),
AIG -2.1% ( expects to report third quarter 2017 pre-tax catastrophe losses net of reinsurance of $2.9 billion to $3.1 billion)
IMPV -1.7% (names Aaron Kuan interim CFO and commences CFO Search; Terry Schmid resigned as CFO to pursue other interests )
Analyst comments:
JBL -3.3% (downgraded to Sell from Neutral at Goldman)
LLY -2.3% (downgraded to Neutral from Outperform at Credit Suisse)
WERN -1.8% (downgraded to Underperform from Neutral at BofA/Merrill)
SYMC -1.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
QLYS -1.2% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
AGCO -1.2% (downgraded to Underweight from Neutral at JP Morgan)
ODFL -0.7% (downgraded to Underperform from Neutral at BofA/Merrill)
EMN -0.5% (downgraded to Neutral from Buy at Nomura)
Briefing.com -
XIMX - Nomura note on $HIMX - Xiaomi’s 3D sensing project may be postponed 2H18 at earliest , also Android 3D sensing may not take off until 2019.
Laenud twitterist, natuke negatiivse varjundiga. Pärsib kogu eelnevat tõusu kuidagi. -
HIMX muidugi. Ma olen tickeri düsgraaf täiesti.
-
Närige seda, OMXT
Kuu tootlus 900%. Sai seal $3+ väikese lossi, kuna oli vale horisont. Kinni pannes oli küll mõtteke, et ilmselt on millalgi double digit, aga et kuu ajaga ten bagger... -
Citron Research @CitronResearch
50s
$hmny stock to trade back to $20 Retail investors are warned. You might like product but $1+bill it isn’t. Giving away $1 for .90 no biz
Läks kallale jälle -
Ta ikka haamerdab järjest VERI, SHOP..... Tänane ajastus perfect tweet, gap up.... top, tugev selling (met first strong sellers), väike bounce ja siis haamer!
-
ymeramees
Citron Research @CitronResearch
50s
$hmny stock to trade back to $20 Retail investors are warned. You might like product but $1+bill it isn’t. Giving away $1 for .90 no biz
Läks kallale jälle
-
Citron Research @CitronResearch
Covering $hmny. Don’t like to stay short companies that are expected to lose money high borrow $ hit tgt price in one day. all timing
